Biopharmas Should Stay Course as High Court Mulls Patent Reviews
Partner Brent Babcock was interviewed in “Biopharmas Should Stay Course as High Court Mulls Patent Reviews,” an article published in Bloomberg BNA.
Excerpt: The U.S. Supreme Court is set to rule in 2018 on whether a federal patent agency review procedure is constitutional, potentially upending administrative reviews of biopharma and medical technology patents.